Treatment Clinical Trials for Soft Tissue Sarcoma

Clinical trials are research studies that involve people. The clinical trials on this list are for soft tissue sarcoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 136

  • Stereotactic Body Radiotherapy in Treating Lung Metastases in Patients with Ewing Sarcoma, Rhabdomyosarcoma, or Wilms Tumors

    This phase I / II trial studies the side effects and best dose of stereotactic body radiotherapy and to see how well it works in treating cancer that has spread to the lung in patients with Ewing sarcoma, rhabdomyosarcoma, or Wilms tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
    Location: 3 locations

  • Preoperative vs Postoperative IMRT for Extremity / Truncal STS

    This study is designed to determine if preoperative image guided radiation therapy (IGRT) delivered using intensity modulated radiation therapy (IMRT) followed by surgery results in similar short-term wound healing complications as surgery followed by postoperative IGRT in patients with extremity or truncal soft tissue sarcoma. Half of the patients will receive preoperative radiotherapy, half will receive postoperative radiotherapy.
    Location: 3 locations

  • A Safety Study of SGN-CD47M in Patients With Solid Tumors

    This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part A and look at how safe and effective the treatment is.
    Location: 2 locations

  • A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

    This is a non-blinded, multi-center, open-label, pilot study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
    Location: 2 locations

  • Intra-lesional Nivolumab in Treating Patients with Cutaneous Kaposi Sarcoma

    This phase I trial studies the side effects of nivolumab injected directly into the lesion and to see how well it works in treating patients with cutaneous Kaposi sarcoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • Epacadostat and Pembrolizumab in Treating Patients with Imatinib-Refractory Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed by Surgery

    This phase II trial studies how epacadostat and pembrolizumab work in treating patients with gastrointestinal stromal tumors that have spread to other places in the body and do not respond to imatinib or that cannot be removed by surgery. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving epacadostat and pembrolizumab may work better in treating patients with gastrointestinal stromal tumors.
    Location: 2 locations

  • Aldesleukin Prodrug NKTR-214 and Nivolumab in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This phase II trial studies how well aldesleukin prodrug NKTR-214 and nivolumab work in treating patients with sarcoma that has spread from where it started to nearby tissue, lymph nodes, or other places in the body (locally advanced or metastatic). Aldesleukin prodrug NKTR-214 is a modified (changed in the laboratory) form of a protein called interleukin-2 (or IL-2) that is normally made by the immune system. This protein is designed to trigger other cells in the immune system to start attacking sarcoma cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving aldesleukin prodrug NKTR-214 and nivolumab may work better in treating patients with sarcoma.
    Location: 2 locations

  • MAGE-A4ᶜ¹º³²T for Multi-Tumor

    This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid / round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.
    Location: 3 locations

  • CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

    This is a multicenter, open-label, phase 1b study of CBP501 / cisplatin / nivolumab combination administered once every 21 days to patients with advanced solid tumors.
    Location: 2 locations

  • Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

    This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study (either with monotherapy or combination therapy). In addition, long-term safety and overall survival will be collected.
    Location: 2 locations

  • A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

    The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
    Location: 3 locations

  • Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors

    Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.
    Location: 2 locations

  • Personalized Cancer Therapy in Treating Participants with Metastatic or Unresectable Cancers

    This pilot trial studies how well personalized cancer therapy works in treating participants with cancer that has spread to other places in the body or cannot be removed by surgery. Personalized cancer therapy is the practice of making decisions about what kind of treatment participants should receive based on the genetic makeup of the tumor. Genes in your body encode certain characteristics such as height, eye and hair color. Researchers believe that abnormal genes in tumors may affect how individuals respond to cancer treatments. Collecting information about tests and treatments received will help researchers describe if patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor.
    Location: 2 locations

  • Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors

    This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
    Location: 3 locations

  • History of the KSHV Inflammatory Cytokine Syndrome (KICS)

    Background: - KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymphoma. Because KICS is a newly identified disease, more information is needed on how the disease works and what can be done to treat it. Objectives: - To collect genetic and medical information from people with KSHV inflammatory cytokine syndrome. Eligibility: - Individuals at least 18 years of age who have Kaposi sarcoma herpes virus and symptoms that resemble those caused by KICS. Design: - Participants will have regular study visits. The schedule will be determined by the study researchers. - Participants will provide a complete medical history and have a full physical exam. Blood and urine samples will be collected as well. - People with KICS that requires treatment may get new experimental treatments. These treatments may include antiviral drugs and chemotherapy drugs, depending on the nature of the disease. - Participants will have imaging studies, such as chest x-rays and computed tomography scans, to study the tumors. - Bone marrow and lymph node biopsies may be done to collect tissue samples for study. - Participants who have Kaposi sarcoma will have photographs taken of their lesions.
    Location: 2 locations

  • A Study of Pembrolizumab plus Local Chemotherapy using Isolated Limb Infusion (ILI) for Patients with Sarcoma in the Arm or Leg

    This phase II trial studies how well pembrolizumab and chemotherapy delivered via isolated limb infusion works in treating patients with sarcoma of the arm or leg that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as melphalan and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Isolated limb infusion delivers chemotherapy to the affected arm or leg. Giving pembrolizumab and isolated limb infusion with melphalan and dactinomycin into the affected arm or leg may delay the time before the disease gets worse (progresses).
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Mocetinostat and Vinorelbine for the Treatment of Locally Advanced Unresectable or Metastatic, Refractory or Relapsed Rhabdomyosarcoma in Children, Adolescents, and Young Adults

    This phase I / II trial studies the side effects and best dose of mocetinostat when given together with vinorelbine and to see how well it works in treating children, adolescents, and young adults with rhabdomyosarcoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or has spread to other places in the body (metastatic), and does not respond to treatment (refractory) or has come back (relapsed). Mocetinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mocetinostat and vinorelbine may work better in treating children, adolescents, and young adults with rhabdomyosarcoma compared to vinorelbine alone.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • DCC-3014 and Avelumab for the Treatment of Locally Advanced or Metastatic High-Grade Sarcoma

    This phase Ib trial studies the side effects and best dose of DCC-3014 and how well it works when given together with avelumab for the treatment of high-grade sarcoma that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). DCC-3014 may help fight cancer by targeting a type of white blood cell called a macrophage. Macrophages are immune cells that are present in or around tumors. Certain macrophages can block the body’s immune system from fighting cancer. Some tumors do not respond to immunotherapy drugs alone because of these macrophages. DCC-3014 may stop macrophages from blocking the immune system and may allow immunotherapy to stimulate the immune system to fight cancer. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DCC-3014 and avelumab may help improve symptoms and shrink or stabilize cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study

    This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Drugs used in chemotherapy, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.
    Location: Mayo Clinic, Rochester, Minnesota

  • Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

    This is a multicenter, double-blind, placebo-controlled, randomized phase 3 study with phase 1b portion designed to establish a recommended phase 3 dose (RP3D) and to evaluate the efficacy, PK, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts.
    Location: 3 locations

  • CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

    This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

    This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Focused Ultrasound for the Promotion of Immune Responses for Resectable Undifferentiated Pleomorphic Sarcoma

    This trial evaluates whether pre-surgical treatment with a high energy ultrasound device is safe and would stimulate the body’s immune system to help fight off a certain kind of tumor, called an undifferentiated pleomorphic sarcoma. This device is called the ExAblate System and the treatment delivered by the ExAblate System device is called “focused ultrasound” treatment. The ExAblate System is a non-invasive thermal ablation device fully integrated with a magnetic resonance (MR) imaging system and used for ablation of soft tissue and bone.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Ipilimumab and Nivolumab with Cryotherapy for the Treatment of Unresectable or Metastatic Soft Tissue Sarcoma

    This phase II trial studies how well ipilimumab and nivolumab with cryotherapy work for the treatment of soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cryotherapy is a procedure that uses extreme cold to kill cancer cells. Cryotherapy may also increase the response to immunotherapy. Giving ipilimumab and nivolumab together with cryotherapy may improve clinical outcomes.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Prexasertib and Irinotecan for the Treatment of Relapsed or Refractory Desmoplastic Small Round Cell Tumor or Rhabdomyosarcoma

    This phase I / II trial studies the best dose, the side effects, and how well prexasertib and irinotecan work in treating patients with desmoplastic small cell tumor or rhabdomysosarcoma that has come back (relapsed) or does not respond to treatment (refractory). Prexasertib is a type of medication called a checkpoint kinase inhibitor. It works by stopping cancer cells from repairing damage to themselves and their deoxyribonucleic acid (DNA) (genes), which may lead to death of cancer cells. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The purpose of this study is to test whether prexasertib is a safe and effective treatment for patients with desmoplastic small round cell tumor or rhabdomyosarcoma when given with irinotecan.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York